← Back to Screener
Rapid Micro Biosystems, Inc. Class A Common Stock (RPID)
Price$2.25
Favorite Metrics
Price vs S&P 500 (26W)-37.72%
Price vs S&P 500 (4W)-12.47%
Market Capitalization$103.66M
All Metrics
Book Value / Share (Quarterly)$0.74
P/TBV (Annual)0.27x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)25.16%
Cash Flow / Share (Quarterly)$-0.72
Price vs S&P 500 (YTD)-25.52%
Gross Margin (TTM)3.12%
Net Profit Margin (TTM)-140.30%
EPS (TTM)$-1.05
10-Day Avg Trading Volume0.20M
EPS Excl Extra (TTM)$-1.05
Revenue Growth (5Y)15.87%
EPS (Annual)$-1.05
ROI (Annual)-90.11%
Gross Margin (Annual)3.12%
Net Profit Margin (5Y Avg)-242.39%
Cash / Share (Quarterly)$0.86
Revenue Growth QoQ (YoY)37.28%
ROA (Last FY)-62.95%
Revenue Growth TTM (YoY)19.74%
EBITD / Share (TTM)$-0.99
ROE (5Y Avg)-63.78%
Operating Margin (TTM)-141.10%
Cash Flow / Share (Annual)$-0.72
P/B Ratio3.12x
P/B Ratio (Quarterly)3.87x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)3.06x
Net Interest Coverage (TTM)-26.71x
ROA (TTM)-58.85%
EPS Incl Extra (Annual)$-1.05
Current Ratio (Annual)3.31x
Quick Ratio (Quarterly)2.32x
3-Month Avg Trading Volume0.24M
52-Week Price Return0.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.01
P/S Ratio (Annual)3.09x
Asset Turnover (Annual)0.45x
52-Week High$4.94
Operating Margin (5Y Avg)-231.19%
EPS Excl Extra (Annual)$-1.05
CapEx CAGR (5Y)4.26%
26-Week Price Return-28.97%
Quick Ratio (Annual)2.32x
13-Week Price Return-38.04%
Total Debt / Equity (Annual)0.57x
Current Ratio (Quarterly)3.31x
Enterprise Value$102.715
Revenue / Share Growth (5Y)13.33%
Asset Turnover (TTM)0.42x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.72x
Pretax Margin (Annual)-140.18%
Cash / Share (Annual)$0.86
3-Month Return Std Dev109.49%
Gross Margin (5Y Avg)-20.96%
Net Income / Employee (TTM)$-0
ROE (Last FY)-141.91%
Net Interest Coverage (Annual)-59.25x
EPS Basic Excl Extra (Annual)$-1.05
Receivables Turnover (TTM)6.22x
Total Debt / Equity (Quarterly)0.57x
EPS Incl Extra (TTM)$-1.05
Receivables Turnover (Annual)6.22x
ROI (TTM)-79.84%
P/S Ratio (TTM)3.09x
Pretax Margin (5Y Avg)-242.91%
Revenue / Share (Annual)$0.75
Tangible BV / Share (Annual)$3.90
Price vs S&P 500 (52W)-35.09%
Year-to-Date Return-21.38%
5-Day Price Return7.04%
EPS Normalized (Annual)$-1.05
ROA (5Y Avg)-41.93%
Net Profit Margin (Annual)-140.30%
Month-to-Date Return0.44%
Cash Flow / Share (TTM)$-1.27
EBITD / Share (Annual)$-0.99
Operating Margin (Annual)-141.10%
LT Debt / Equity (Annual)0.57x
ROI (5Y Avg)-53.35%
LT Debt / Equity (Quarterly)0.57x
EPS Basic Excl Extra (TTM)$-1.05
P/TBV (Quarterly)0.35x
P/B Ratio (Annual)3.87x
Inventory Turnover (TTM)1.72x
Pretax Margin (TTM)-140.18%
Book Value / Share (Annual)$0.74
Price vs S&P 500 (13W)-40.91%
Beta1.55x
Revenue / Share (TTM)$0.74
ROE (TTM)-95.40%
52-Week Low$2.01
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.20
Industry Peers — Lab Analytical Instruments(22)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
RPIDRapid Micro Biosystems, Inc. Class A Common Stock | 3.09x | 15.87% | 3.12% | -141.10% | $2.25 |
AAgilent Technologies Inc. | 4.83x | 5.41% | 52.60% | 20.40% | $120.96 |
WATWaters Corp | 10.18x | 6.00% | 59.28% | 25.36% | $335.61 |
MTDMettler-Toledo International | 6.66x | 5.47% | 59.37% | 26.05% | $1324.66 |
ILMNIllumina Inc | 4.69x | 6.04% | 66.61% | 18.44% | $132.86 |
RVTYRevvity, Inc. | 3.64x | -5.46% | 54.77% | 12.49% | $93.03 |
BIOBio-Rad Laboratories, Inc.Class A | 3.17x | 0.29% | 52.01% | 1.59% | $303.34 |
BIO.BBio-Rad Laboratories, Inc. Class B | 3.17x | 0.29% | 52.01% | 1.59% | $277.00 |
BRKRBruker Corporation | 1.81x | 11.57% | 47.13% | 1.40% | $41.10 |
BRKRPBruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A | 1.81x | 11.57% | 47.13% | 1.40% | $320.13 |
AVTRAvantor, Inc. | 0.88x | 0.49% | 32.65% | -3.83% | $8.50 |
About
Rapid Micro Biosystems automates microbial quality control testing for pharmaceutical and biotech manufacturers. Its Growth Direct platform modernizes manual testing workflows used in the production of biologics, vaccines, cell and gene therapies, and sterile injectables. The company generates revenue through system sales, consumables, software licensing, and related services.